Patents by Inventor Rudi E. Moerck

Rudi E. Moerck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140308345
    Abstract: A method of enhancing cardiovascular health includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S?-astaxanthin derived from Haematococcus pluvialis.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 16, 2014
    Inventors: JOHN A. MINATELLI, W. STEPHEN HILL, RUDI E. MOERCK
  • Publication number: 20140302136
    Abstract: A medicine delivery system delivers medicine such as a dietary supplement to improve prostate health and includes an outer capsule containing a saw palmetto extract and an inner capsule within the outer capsule and containing a carotenoid. The outer capsule is formed to dissolve in the stomach when ingested to release the saw palmetto extract into the stomach and the inner capsule is formed to pass into the duodenum to dissolve and release the carotenoid into the duodenum.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 9, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. MINATELLI, W. Stephen HILL, Rudi E. MOERCK
  • Patent number: 8852543
    Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: October 7, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
  • Publication number: 20140294987
    Abstract: A composition of matter comprises a shelf stable, super critical, CO2 fluid extracted seed oil derived from a cracked biomass of perilla frutescens, the seed oil comprising from about 60 to about 95 percent w/w of PUFAs in a ratio of from about 4:1 to about 6:1 alpha-linolenic acid (ALA) to linoleic acid (LA) and a mixture of selected antioxidants.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 2, 2014
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck, Uy Nguyen
  • Publication number: 20140248369
    Abstract: A dietary supplement composition is formulated in a therapeutically effective amount to treat the eye of an individual. The composition includes a perilla seed oil extract, astaxanthin, and at least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin and meso-zeaxanthin.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: JOHN A. MINATELLI, W. STEPHEN HILL, RUDI E. MOERCK, UY NGUYEN
  • Publication number: 20140205627
    Abstract: In accordance with a non-limiting example, an algae based oil is used in place of a krill oil to treat low density lipoprotein (LDL) oxidation in humans by administering a therapeutic amount of a dietary supplement composition comprising an algae based oil comprising glycolipids and phospholipids and Eicosapentaenoic (EPA) fatty acids in combination with astaxanthin derived from Haematococcus pluvialis (Hp) in an oral dosage form, wherein the astaxanthin derived from Haematococcus pluvialis (Hp) is 0.1 to 2.7 percent by weight of the algae based oil.
    Type: Application
    Filed: March 19, 2014
    Publication date: July 24, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: JOHN A. MINATELLI, W. STEPHEN HILL, RUDI E. MOERCK
  • Publication number: 20140205675
    Abstract: A horse feed dietary supplement composition increases the energy and improves the health and coat of a horse and is formed as a partially defatted seed meal composition that may be supplemented to a horse feed. The composition includes a shelf stable, partially defatted supercritical CO2 fluid solvent extracted whole grain flour that is derived from Salvia hispanica L. whole ground seed and that is free of cyanogenic glycosides, vitamin antagonists, and gluten. The flour includes minerals, protein, insoluble fiber and from 1-25% wt/wt of about 3.0-3.3:1 mixture of ALA to LA native seed oil.
    Type: Application
    Filed: March 24, 2014
    Publication date: July 24, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. MINATELLI, W. Stephen HILL, Rudi E. MOERCK, Uy NGUYEN
  • Patent number: 8784904
    Abstract: A composition of matter comprises a shelf stable, super critical, CO2 fluid extracted seed oil derived from a cracked biomass of perilla frutescens, the seed oil comprising from about 60 to about 95 percent w/w of PUFAs in a ratio of from about 4:1 to about 6:1 alpha-linolenic acid (ALA) to linoleic acid (LA) and a mixture of selected antioxidants.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: July 22, 2014
    Assignee: U.S. Nutraceuticals, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck, Uy Nguyen
  • Publication number: 20140199342
    Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a patient. The composition includes an algae based oil having glycolipids and phospholipids and Eicosapentaenoic (EPA) fatty acids in combination with astaxanthin and low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) and a molecular weight less than 300 kilodaltons (kDa) in an oral dosage form.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Publication number: 20140178488
    Abstract: A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids. The krill oil includes at least 10% EPA and 5% DHA, of which greater than 50% are in the form of phospholipids and the 1-4000 mg of krill oil per daily dose is delivered.
    Type: Application
    Filed: February 26, 2014
    Publication date: June 26, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Publication number: 20140161702
    Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
    Type: Application
    Filed: January 7, 2014
    Publication date: June 12, 2014
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
  • Publication number: 20140154345
    Abstract: A composition of matter comprises a shelf stable, partially defatted supercritical CO2 fluid solvent extracted whole grain flour derived from a cracked biomass of perilla frutescens, the flour comprising minerals and 2 to 8 percent of native seed oil, 35 to 45 percent protein, and 35 to 45 percent fiber.
    Type: Application
    Filed: February 6, 2014
    Publication date: June 5, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck, Uy Nguyen
  • Publication number: 20140148405
    Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.
    Type: Application
    Filed: January 30, 2014
    Publication date: May 29, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. MINATELLI, W. STEPHEN HILL, RUDI E. MOERCK
  • Patent number: 8728531
    Abstract: A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids. The krill oil includes at least 10% EPA and 5% DHA, of which greater than 50% are in the form of phospholipids and the 1-4000 mg of krill oil per daily dose is delivered.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: May 20, 2014
    Assignee: U.S. Nutraceuticals, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Publication number: 20140128341
    Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.
    Type: Application
    Filed: December 17, 2013
    Publication date: May 8, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Patent number: 8715603
    Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: May 6, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Rudi E. Moerck, Timothy Malcome Spitler, Edward A Schauer, Jan Prochazka
  • Publication number: 20140120234
    Abstract: A composition of matter includes a shelf-stable, partially defatted supercritical CO2 fluid solvent extracted whole grain flour derived from Salvia hispanica L. whole ground seed and that is free of cyanogenic glycosides, vitamin antagonists, and gluten. The flour includes minerals, about 25-35% protein, about 5-8% wt/wt of about 3.0-3.3:1 mixture of ALA to LA native seed oil, and about 48-60% insoluble fiber. The flour exhibits pH dependent thixotropic properties when mixed with water.
    Type: Application
    Filed: December 11, 2013
    Publication date: May 1, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: JOHN A. MINATELLI, W. STEPHEN HILL, RUDI E. MOERCK, UY NGUYEN
  • Publication number: 20140087050
    Abstract: A composition of matter is disclosed and formed from a stable, defatted whole grain flour derived from Salvia hispanica L. whole ground seed using a suitable solvent that is free of cyanogenic glycosides, vitamin antagonists, and gluten. The composition includes minerals, about 30% wt/wt protein, about 30-40% insoluble fiber and about 2-3% of fructo-oligosaccarides.
    Type: Application
    Filed: December 3, 2013
    Publication date: March 27, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. MINATELLI, W. Stephen HILL, Rudi E. MOERCK, Uy NGUYEN
  • Patent number: 8663704
    Abstract: A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids. The krill oil includes at least 10% EPA and 5% DHA, of which greater than 50% are in the form of phospholipids and the 1-4000 mg of krill oil per daily dose is delivered.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: March 4, 2014
    Assignee: U.S. Nutraceuticals, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Publication number: 20140023634
    Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.
    Type: Application
    Filed: September 5, 2013
    Publication date: January 23, 2014
    Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
    Inventors: John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck